Company Filing History:
Years Active: 2021
Title: Su Jin Ahn: Innovator in Fusion Protein Technology
Introduction
Su Jin Ahn is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. His work focuses on enhancing the pharmacological properties of therapeutic agents.
Latest Patents
Su Jin Ahn holds a patent for a fusion protein comprising a CCL3 variant. This innovative protein demonstrates improved in vivo persistency, protein stability, and pharmacological activity. The patent details a fusion protein that includes a CCL3 variant and an immunoglobulin Fc region, which can be utilized as a therapeutic agent for conditions such as lymphopenia, cancer, or infection. The CCL3 variant is characterized by a deletion of an N-terminal amino acid from the wild-type CCL3α or CCL3β, along with a specific amino acid substitution.
Career Highlights
Su Jin Ahn is currently employed at Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on innovative solutions in the field of medicine and biotechnology. His contributions have been instrumental in advancing therapeutic options for various diseases.
Collaborations
Su Jin Ahn collaborates with talented colleagues, including Su Youn Nam and Jong Gyun Kim. These partnerships enhance the research and development efforts at Yuhan Corporation, fostering an environment of innovation and creativity.
Conclusion
Su Jin Ahn's work in fusion protein technology exemplifies the impact of innovative thinking in biotechnology. His patent for a CCL3 variant fusion protein highlights his commitment to improving therapeutic agents. Through his career at Yuhan Corporation, he continues to contribute to advancements in medical science.